AZD3759: A Breakthrough CNS-Penetrant EGFR TKI for EGFR-Mutant NSCLC with Brain Metastasis
Targeting EGFR-mutated NSCLC with brain metastases: Discover the potent CNS penetration of AZD3759.
Get a Quote & SampleProduct Core Value
AZD3759
AZD3759 is a novel Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor meticulously engineered for superior central nervous system (CNS) penetration, addressing a critical unmet need in the treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) with brain metastases.
- Introducing AZD3759, a potent EGFR TKI designed for exceptional CNS penetration, crucial for effectively treating EGFR-mutated NSCLC brain metastases.
- Explore the significant advantages of AZD3759's high CNS penetration, a key factor in overcoming the blood-brain barrier for targeted cancer therapies.
- Learn about the durable response observed with AZD3759 in clinical trials, showcasing its efficacy in managing complex NSCLC CNS disease.
- Discover how AZD3759 offers a more favorable option compared to earlier EGFR TKIs for patients battling advanced NSCLC with intracranial involvement.
Advantages Offered by the Product
Enhanced Brain Penetration
AZD3759 exhibits superior blood-brain barrier (BBB) penetration, a critical factor for effective EGFR-mutated NSCLC brain metastasis treatment, ensuring therapeutic drug concentrations reach the tumor site.
Potent Efficacy
As a powerful EGFR inhibitor, AZD3759 demonstrates significant antitumor activity in preclinical and clinical settings, offering hope for patients with limited treatment options.
Long-Term Response
The case studies highlight the potential for prolonged and sustained responses, showcasing the durable efficacy of zorifertinib efficacy in managing both intracranial and extracranial lesions.
Key Applications
Oncology Treatment
AZD3759 is a key agent in the fight against EGFR-mutated NSCLC, particularly when central nervous system involvement is present, representing a major step forward in targeted cancer therapies for brain metastases.
Pharmaceutical Research
As an API, AZD3759 is vital for ongoing research into advanced cancer treatments and understanding the dynamics of BBB penetrating EGFR inhibitors, driving innovation in oncology drug development pipeline.
Targeted Therapy Development
Its specific mechanism of action makes it a cornerstone for developing new EGFR mutation targeted therapies, aiming to improve patient outcomes and quality of life in NSCLC CNS disease management.
Chemical Synthesis
AZD3759 also serves as a critical component in pharmaceutical intermediates research, supporting the synthesis of complex molecules essential for drug discovery and production.